LLY Stock Recent News
LLY LATEST HEADLINES
Eli Lilly's tirzepatide aced a pair of clinical trials. The medicine's sales potential looks mouthwatering.
Healthcare stocks can offer investors more predictable growth opportunities than artificial intelligence, where there's much more uncertainty in the long run. Eli Lilly and Novo Nordisk have top drugs that can help diabetes and obesity, two significant health concerns around the world.
Eli Lilly is the developer of GLP-1 treatments Mounjaro and Zepbound. Currently used to treat diabetes and obesity, they could have far more reach.
Eli Lilly (LLY) reports earnings before the bell Tuesday, with investors and analysts watching to see how much weight-loss drugs are continuing to drive the company's growth.
Eli Lilly stock (NYSE: LLY) will report its Q1 results on Tuesday, April 30. The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the consensus estimates.
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Blue-chip growth stocks are all around us. Yet, finding the right fit for your particular portfolio is easier said than done.
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Demand is high for Eli Lilly's Zepbound, and the weight-loss drug market could reach $100 billion by the end of the decade. But one thing is getting in between some potential patients and this promising drug.